Resection and Defect Repair of Oral Cancer Aided by Mixed Reality Technology

March 18, 2026 updated by: Mingming Lv, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Prospective Clinical Study in Resection and Defect Repair of Oral Cancer Aided by Mixed Reality Technology Based on UE5 Engine

The objective of this exploratory clinical trial is to apply Unreal Engine 5 (UE5)-based Mixed Reality (MR) technology to achieve real-time stereoscopic visualization of surgical planning, personalized free flap harvest and defect reconstruction, accurate oral cancer resection, and precise morphological and volumetric matching of the reconstructed free flap to the defect site.

Researchers adopted a parallel controlled design, with participants randomized into three groups: Experimental Group 1 (undergoing Mixed Reality [MR] technology-assisted surgery), Experimental Group 2 (undergoing virtual surgical guide-assisted surgery), and Control Group (undergoing conventional surgery). A total of 30 participants will be recruited, with 10 cases in each group.

The primary purpose is to confirm the effectiveness of MR technology in assisting oral cancer resection, free flap design, harvest, and defect reconstruction. Allocation concealment will be implemented via the sealed envelope method.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Study population: Patients with oral cancer confirmed by preoperative pathology (tumor diameter > 3 cm), who had defects suitable for free flap reconstruction, signed written informed consent, agreed to complete postoperative follow-up, and were medically eligible for major surgery. This study was conducted at the Department of Oral and Maxillofacial-Head and Neck Oncology, the Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine.

The study is conducted at the Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine.

Primary research questions & outcome assessments:

  1. Whether UE5-based MR technology enables precise morphological and volumetric matching of free flaps in oral cancer reconstruction.
  2. Comparisons of operative duration, flap characteristics (utilization, volume, survival), and primary wound healing rate between mixed reality (MR), virtual surgical guide, and conventional surgery.
  3. Whether MR technology can overcome the limitations of virtual surgical guide systems and further enhance surgical efficiency and precision.

Researchers adopted a parallel controlled design, with participants randomized into three groups: Experimental Group 1 (undergoing Mixed Reality [MR] technology-assisted surgery), Experimental Group 2 (undergoing virtual surgical guide-assisted surgery), and Control Group (undergoing conventional surgery). A total of 30 participants will be recruited, with 10 cases in each group. The primary purpose is to confirm the effectiveness of MR technology in assisting oral cancer resection, free flap design, harvest, and defect reconstruction. Allocation concealment will be implemented via the sealed envelope method.

During the study period, participants will be required to complete the following main tasks and receive relevant interventions:

Preoperatively: Cooperate with computed tomography (CT) data acquisition and complete ultrasonic localization/computed tomography angiography (CTA) examinations (for flap region localization, identification of perforator positions and flap thickness, and corresponding body surface marking). Participants will also collaborate with researchers to design the tumor resection margin, as well as the shape and volume of the free flap to be harvested. After signing the informed consent form, participants will receive surgical treatment corresponding to their randomization assignment.

Intraoperatively: Following the onset of general anesthesia, participants will cooperate with routine surgical skin preparation and draping. For participants in Experimental Group 1, registration and fusion must be completed prior to the initiation of formal surgery to ensure the registration accuracy of MR technology during the operation. In accordance with the preoperative surgical plan, precise tumor resection, free flap harvest, and defect reconstruction will be performed with MR guidance.

Postoperatively: Complete follow-up visits as required, including outpatient follow-ups at 2 weeks ± 3 days, 1 month ± 7 days, 3 months ± 2 weeks, and 6 months ± 1 month postoperatively. Participants will cooperate with physical examinations, CT/magnetic resonance imaging (MRI) scans, and Likert scale assessments, and assist researchers in collecting surgery-related and postoperative recovery data. CT scans will be performed at 1 month and 6 months postoperatively; engineers will import the CT data into a computer, fuse it with the preoperative design scheme, and calculate the morphological similarity (expressed as a percentage).

During the study period, participants must promptly inform researchers if disease progression, complications, or other conditions precluding continued study participation occur. Participants may voluntarily withdraw from the study at any time without affecting their standard medical care.

Participants shall cooperate with researchers in data collection and refrain from participating in other clinical studies or related treatments that may interfere with the results of this study.

Study Type

Interventional

Enrollment (Estimated)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • China
      • Shanghai, China
        • Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Definite pathological diagnosis of oral cancer before surgery;
  2. Defects suitable for free flap reconstruction;
  3. Patients have signed the informed consent form and are willing to cooperate with postoperative follow-up.

Exclusion Criteria:

- Poor general condition, evaluated as unable to tolerate surgical treatment.

-Exclusion Criteria (After Enrollment)

Subjects who have been enrolled in this trial will be excluded if they meet any of the following conditions:

  1. Violation of important inclusion criteria;
  2. Subjects did not receive surgical treatment;
  3. No observation data after randomization. Withdrawal Criteria Withdrawal of subjects from the trial refers to cases where enrolled subjects are determined by the investigator to withdraw from the trial due to conditions that make it inappropriate to continue the trial. In accordance with the informed consent form, subjects have the right to withdraw from the trial midway. Subjects who do not explicitly propose to withdraw but stop receiving treatment and tests and are lost to follow-up are also considered "withdrawn" (or "lost to follow-up"). The reason for withdrawal should be understood and recorded as much as possible, such as: poor subjective curative effect; inability to tolerate certain adverse reactions; inability to continue participating in the clinical study due to personal reasons; economic factors; or lost to follow-up without stating the reason.

(1) Aggravation or deterioration of the condition during the trial that requires emergency measures; (2) Occurrence of certain comorbidities, complications or special physiological changes in subjects during the trial, making it inappropriate to continue participating in the trial; (3) Voluntary withdrawal by the subject.

Data Handling of Withdrawn Subjects

Regardless of the reason, the complete clinical data of subjects who withdraw from the trial shall be retained. For all withdrawn subjects, the trial conclusion form and the reason for withdrawal shall be filled in the case report form (CRF). Generally, there are 6 types of reasons: occurrence of adverse events (including adverse drug reactions and allergic reactions), lack of efficacy (deterioration of condition or occurrence of complications), violation of the trial protocol (including poor compliance), lost to follow-up (including voluntary withdrawal by the patient), termination by the sponsor, or others.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Control Group (Conventional Surgery)
Adoption of traditional surgical methods for oral cancer resection and defect repair; no auxiliary technologies such as mixed reality or virtual guides are used, and tumor resection and flap repair are completed relying on the clinician's clinical experience.
Experimental: Experimental Group 1 (Mixed Reality Technology)
Application of Mixed Reality (MR) technology based on the UE5 engine to assist in oral cancer resection and defect repair; realize real-time three-dimensional visualization of surgical plans, precise resection of oral cancer, "tailor-made" flap harvesting, and match the shape and volume of the defect site.
Procedure: Unreal Engine 5 (UE5)-based Mixed Reality (MR) Technology-assisted Resection of Oral Cancer and Defect Reconstruction
Intervention Description: Assisted oral cancer resection and defect reconstruction using MR technology based on UE5 engine, to achieve real-time stereoscopic visualization of surgical planning, accurate tumor resection and personalized free flap harvest, ensuring the reconstructed flap matches the defect site in morphology and volume.
Experimental: Experimental Group 2 (Virtual Surgical Guide)
Application of virtual surgical guide technology to assist in oral cancer resection and defect repair; assist surgery relying on pre-designed and manufactured guides to improve surgical standardization; guide printing is required before surgery, and the plan cannot be adjusted in real time during surgery.
Procedure: Virtual Surgical Guide Technology-assisted Resection of Oral Cancer and Defect Reconstruction
Intervention Description: Assisted oral cancer resection and defect reconstruction using virtual surgical guide technology, with surgery performed under the guidance of preoperatively designed and fabricated guides to improve surgical standardization.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Morphological and Volumetric Matching Degree of Free Flap Reconstruction
Time Frame: Preoperatively 2 weeks ± 3 days postoperatively 1 month ± 7 days postoperatively 3 months ± 2 weeks postoperatively 6 months ± 1 month postoperatively
Description: Computed Tomography (CT) scans will be performed at 1 month and 6 months postoperatively. CT data will be fused with the preoperative design scheme to calculate morphological similarity (expressed as a percentage), so as to evaluate the morphological and volumetric matching effect between the reconstructed flap and the defect site in the three groups. The core purpose is to compare the precision of MR technology with the other two methods.
Preoperatively 2 weeks ± 3 days postoperatively 1 month ± 7 days postoperatively 3 months ± 2 weeks postoperatively 6 months ± 1 month postoperatively

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Surgery-related Indicators
Time Frame: Preoperatively 2 weeks ± 3 days postoperatively 1 month ± 7 days postoperatively 3 months ± 2 weeks postoperatively 6 months ± 1 month postoperatively
The operative duration and utilization rate of harvested free flaps will be recorded in the three groups to evaluate the impact of different adjuvant technologies on surgical efficiency.
Preoperatively 2 weeks ± 3 days postoperatively 1 month ± 7 days postoperatively 3 months ± 2 weeks postoperatively 6 months ± 1 month postoperatively
Postoperative Recovery Indicators
Time Frame: Preoperatively 2 weeks ± 3 days postoperatively 1 month ± 7 days postoperatively 3 months ± 2 weeks postoperatively 6 months ± 1 month postoperatively
The free flap survival rate and primary wound healing rate will be counted in the three groups; the incidence of postoperative complications will be observed to evaluate surgical safety and reconstruction efficacy.
Preoperatively 2 weeks ± 3 days postoperatively 1 month ± 7 days postoperatively 3 months ± 2 weeks postoperatively 6 months ± 1 month postoperatively

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Investigators

  • Principal Investigator: mingming lv, Associate Professor, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

April 1, 2026

Primary Completion (Estimated)

April 1, 2027

Study Completion (Estimated)

October 1, 2027

Study Registration Dates

First Submitted

March 7, 2026

First Submitted That Met QC Criteria

March 7, 2026

First Posted (Actual)

March 12, 2026

Study Record Updates

Last Update Posted (Actual)

March 20, 2026

Last Update Submitted That Met QC Criteria

March 18, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • SH9H-2024-T403-1

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

IPD will not be shared because the study involves sensitive patient data related to head and neck cancer surgery, including clinical, imaging, and surgical outcome information that could compromise patient privacy and confidentiality if shared. Additionally, the study is still in progress, and premature sharing of IPD may compromise the integrity of the primary analysis and publication plans. Restrictions on IPD sharing are also imposed by the institutional review board (IRB) and ethical guidelines to protect the rights and welfare of study participants, as well as by the data use agreements with participating institutions.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Oral Cancer

Clinical Trials on Unreal Engine 5 (UE5)-based Mixed Reality (MR) Technology-assisted Resection of Oral Cancer and Defect Reconstruction

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Estonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe